Health & Fitness
Thu, February 7, 2013Wed, February 6, 2013Tue, February 5, 2013Mon, February 4, 2013Sun, February 3, 2013Sat, February 2, 2013Fri, February 1, 2013Thu, January 31, 2013Wed, January 30, 2013Tue, January 29, 2013Mon, January 28, 2013Sun, January 27, 2013Sat, January 26, 2013Fri, January 25, 2013Thu, January 24, 2013Wed, January 23, 2013Tue, January 22, 2013Mon, January 21, 2013Fri, January 18, 2013Thu, January 17, 2013Wed, January 16, 2013Tue, January 15, 2013Medifocus Inc. Announces Shares for Debt Transaction
Published in Health and Fitness on Tuesday, January 29th 2013 at 7:15 GMT by Market Wire
January 29, 2013 09:59 ET
Medifocus Inc. Announces Shares for Debt Transaction
TORONTO, ONTARIO--(Marketwire - Jan. 29, 2013) - Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) has agreed, subject to regulatory approval, to issue an aggregate of 1,090,000 common shares at a deemed price of $0.25 per common share to settle an aggregate of $272,500 of debt representing unpaid salary ($210,000) and amounts due to service providers ($62,500).
All of the common shares issued in connection with the shares for debt transaction will subject to a 4-month and one day hold period from the date of issuance.
About Medifocus
Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array (APA) technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. With the acquisition of Prolieve®, Medifocus now owns in addition, a revenue generating commercial BPH heat treatment product generating cash flow to support the development and commercialization of other catheter based or APA based external focused heat systems for targeted thermotherapy of deep seated tumors anywhere in the body. Please visit [ www.medifocusinc.com ] for more details.
Forward-Looking Statements and Information
This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required under applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
